Burger's Medicinal Chemistry, Drug Discovery and Development, 8 Volume Set
Shipping & Delivery
Our Delivery Time Frames Explained
2-4 Working Days: Available in-stock
10-20 Working Days: On Backorder
Will Deliver When Available: On Pre-Order or Reprinting
We ship your order once all items have arrived at our warehouse and are processed. Need those 2-4 day shipping items sooner? Just place a separate order for them!
Product details
- ISBN 9781119530305
- Weight: 10455g
- Dimensions: 185 x 259mm
- Publication Date: 22 Apr 2021
- Publisher: John Wiley & Sons Inc
- Publication City/Country: US
- Product Form: Hardback
Explore the freshly updated flagship reference for medicinal chemists and pharmaceutical professionals
The newly revised eighth edition of the eight-volume Burger’s Medicinal Chemistry, Drug Discovery and Development is the latest installment in this celebrated series covering the entirety of the drug development and discovery process. With the addition of expert editors in each subject area, this eight-volume set adds 35 chapters to the extensive existing chapters. New additions include analyses of opioid addiction treatments, antibody and gene therapy for cancer, blood-brain barrier, HIV treatments, and industrial-academic collaboration structures.
Along with the incorporation of practical material on drug hunting, the set features sections on drug discovery, drug development, cardiovascular diseases, metabolic diseases, immunology, cancer, anti-Infectives, and CNS disorders. The text continues the legacy of previous volumes in the series by providing recognized, renowned, authoritative, and comprehensive information in the area of drug discovery and development while adding cutting-edge new material on issues like the use of artificial intelligence in medicinal chemistry.
Included:
Perfect for research departments in the pharmaceutical and biotechnology industries, Burger’s Medicinal Chemistry, Drug Discovery and Development can be used by graduate students seeking a one-stop reference for drug development and discovery and deserves its place in the libraries of biomedical research institutes, medical, pharmaceutical, and veterinary schools.
Donald J. Abraham is Emeritus Professor of Medicinal Chemistry and Emeritus Director of the Institute for Structural Biology and Drug Discovery at Virginia Commonwealth University. He is a member of the Hall of Fame of the American Chemical Society’s Medicinal Chemistry Division.
Michael Myers, PhD is Senior Director of Due Diligence at Lilly Research Labs. He has worked in drug discovery and development for over 30 years. He holds over 35 patents and has led efforts in evaluating new lead generation technologies and processes in early drug discovery, predictive ADMET, and computational chemistry.
Kent D. Stewart, PhD (Volume Editor) is Associate Professor of Basic Pharmaceutical Sciences at High Point University. Previously, he worked for over 25 years in the industry at Burroughs Wellcome, AbbVie, and Abbott Laboratories.
